Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
P/B ratio for Fusion Antibodies plc (FAB)
P/B ratio as of September 2026 TTM: 14.42
According to Fusion Antibodies plc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 14.42. At the end of 2024 the company had a P/B ratio of 1.19.
P/B ratio history for Fusion Antibodies plc from 2013 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 14.42 63.73%
2025 8.81 638.88%
2024 1.19 -86.62%
2023 8.92 111.06%
2022 4.23 -49.81%
2021 8.42 93.06%
2020 4.36 270.89%
2019 1.18 -54.53%
2018 2.59 -83.83%
2017 15.99 -14.59%
2016 18.73 -88.38%
2015 161.16 -102.17%
2014 -7.41K -918.70%
2013 905.56 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 -54.84%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 -48.71%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 -40.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 -72.29%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH